{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:20:06Z","timestamp":1774765206384,"version":"3.50.1"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate rates of clinically inactive disease (CID) and remission in patients with juvenile idiopathic arthritis (JIA) receiving tofacitinib using the 2021 Juvenile Arthritis Disease Activity Score (JADAS) thresholds and American College of Rheumatology (ACR) criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis included patients with active JIA (polyarticular-course JIA, psoriatic arthritis, or enthesitis-related arthritis) enrolled in a phase III randomized withdrawal study of tofacitinib. In part 1 (weeks 0-18), patients received open-label tofacitinib. In part 2 (weeks 18-44), patients who achieved ACR improvement \u2265 30% were randomized to tofacitinib or placebo for 26 weeks or until JIA flare. Disease activity was assessed using the JADAS in 10 joints (JADAS10) based on C-reactive protein, with interpretation according to 2021 polyarthritis thresholds. JADAS10 remission was defined as \u2265 24 continuous weeks of JADAS10 CID (JADAS10-CID). ACR CID (ACR-CID) and ACR clinical remission were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 225 patients with JIA in part 1, 173 (76.9%) were randomized in part 2 to continue tofacitinib or switch to placebo. Rates of JADAS10-CID and ACR-CID increased throughout part 1 to 30.5% and 15.8% (week 18), respectively. In part 2, these were sustained with tofacitinib (week 44: 35.2% [JADAS10-CID], 25% [ACR-CID]) and decreased when patients switched to placebo (week 44: 25.9% [JADAS10-CID], 15.3% [ACR-CID]). A small proportion of patients achieved JADAS10 remission at week 44 (tofacitinib: 14.8%; placebo: 7.1%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time, and a small proportion of patients achieved JADAS10 remission. Inactive disease is a feasible treatment target in patients receiving tofacitinib. (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02592434\">NCT02592434<\/jats:ext-link>)<\/jats:p>\n               <\/jats:sec>","DOI":"10.3899\/jrheum.2024-0536","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:20:12Z","timestamp":1746087612000},"page":"919-926","source":"Crossref","is-referenced-by-count":3,"title":["Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7614","authenticated-orcid":false,"given":"Alessandro","family":"Consolaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1072-3782","authenticated-orcid":false,"given":"Olga","family":"Synoverska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5831","authenticated-orcid":false,"given":"Carlos","family":"Abud-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3237-9962","authenticated-orcid":false,"given":"Yulia","family":"Vyzhga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-4721","authenticated-orcid":false,"given":"Ekaterina","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1107-0923","authenticated-orcid":false,"given":"Jeffrey","family":"Chaitow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-1384","authenticated-orcid":false,"given":"Peter","family":"Chiraseveenuprapund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Lazariciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5775","authenticated-orcid":false,"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2025090105350882000_52.9.919.1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/acr.24384","article-title":"Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025090105350882000_52.9.919.2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"2025090105350882000_52.9.919.3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2025090105350882000_52.9.919.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.24477"},{"key":"2025090105350882000_52.9.919.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23916"},{"key":"2025090105350882000_52.9.919.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216843"},{"key":"2025090105350882000_52.9.919.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213030"},{"key":"2025090105350882000_52.9.919.8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025090105350882000_52.9.919.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2025090105350882000_52.9.919.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2025090105350882000_52.9.919.11","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2025090105350882000_52.9.919.12","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score cutoffs for disease activity states in juvenile idiopathic arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350882000_52.9.919.13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025090105350882000_52.9.919.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"2025090105350882000_52.9.919.15","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.188946"},{"key":"2025090105350882000_52.9.919.16","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2025090105350882000_52.9.919.17","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2025090105350882000_52.9.919.18","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090105350882000_52.9.919.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200237"},{"key":"2025090105350882000_52.9.919.20","first-page":"S1","article-title":"Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology","volume":"19","author":"Ruperto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2025090105350882000_52.9.919.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2025090105350882000_52.9.919.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120842"},{"key":"2025090105350882000_52.9.919.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"2025090105350882000_52.9.919.24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12969-023-00814-x","article-title":"The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from the Finnish Rheumatology Quality Register","volume":"21","author":"Backstr\u00f6m","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025090105350882000_52.9.919.25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/diagnostics12010182","article-title":"High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or Jak inhibitors: a clinical and ultrasonographic study","volume":"12","author":"Frade-Sosa","year":"2022","journal-title":"Diagnostics"},{"key":"2025090105350882000_52.9.919.26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin Arthritis Rheum"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:35:39Z","timestamp":1756730139000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.3899\/jrheum.2024-0536"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0536","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}